跳至主要内容
临床试验/KCT0009443
KCT0009443已完成Unknown

Clinical trial to evaluate the safety and efficacy for improvement trapezius hypertrophy of botulax® injection.

Asan Medical Center0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症

试验速览

阶段
Unknown
状态
已完成
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20(Year) 至 60(Year)(—)
性别
All

入选标准

  • 1) A person between the ages of 20 and 60 who want contour correction of the gastrocnemius muscle
  • 2) A person who can follow the clinical trial procedure well and abide by the visit schedule
  • 3) Those who voluntarily signed the consent form

排除标准

  • 1) Patients with diseases that can affect neuromuscular function, such as myasthenia gravis, Eaton-Lamberton syndrome, amyotrophic lateral sclerosis, and motor neuropathy
  • 2) Aminoglycoside antibiotics, curare-like agents, or drugs that inhibit neuromuscular function (muscle relaxants such as tubocurarine, dancrolen sodium, and baclofen, anticholinergics, and benzodiazepines) antibiotics, benzamide, tetracycline, lincomycin antibiotics, etc.)
  • 3) Patients with a history of recent alcoholism or drug misuse
  • 4) Patients with skin abnormalities such as infections, skin diseases, or scars at the injection site
  • 5) If you have had other procedures that may affect gastrocnemius treatment within 6 months prior to baseline
  • 6) Those who have received botulinum toxin preparations within 6 months before baseline
  • 7) Patients with a history of facial nerve palsy or ptosis
  • 8) Those taking aspirin, NSAIDs or anticoagulants
  • 9) A woman who is pregnant, lactating, or of childbearing potential who does not agree to contraception by a medically accepted method for up to 8 weeks after drug administration
  • 10) A person who has rapidly lost weight
  • 11) Patients who are allergic or sensitive to investigational drugs or their ingredients
  • 12) Those who are currently suffering from an acute disease
  • 13) Those suffering from severe heart disease or respiratory disease
  • 14) Patients who have participated in another clinical trial within 30 days before baseline or who have not passed the longer period of 5 times the half-life of the investigational drug of the clinical trial they participated in
  • 15) Other patients who are not suitable for this test under the judgment of the investigator

研究者

相似试验

Clinical trial to evaluate the safety and efficacy... | 临床试验